145 related articles for article (PubMed ID: 34894128)
1. Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen-Positive Patients.
Chen CH; Peng CY; Kuo YH; Hu TH; Hung CH; Wang JH; Lu SN
J Infect Dis; 2022 Jun; 225(11):1974-1981. PubMed ID: 34894128
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir.
Kuo MT; Hu TH; Hung CH; Wang JH; Lu SN; Tsai KL; Chen CH
Aliment Pharmacol Ther; 2019 Jan; 49(2):218-228. PubMed ID: 30484881
[TBL] [Abstract][Full Text] [Related]
3. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
[No Abstract] [Full Text] [Related]
4. Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B.
Chen CH; Peng CY; Hu TH; Wang JH; Hung CH; Lu SN
Aliment Pharmacol Ther; 2023 Aug; 58(3):334-345. PubMed ID: 37265196
[TBL] [Abstract][Full Text] [Related]
5. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
[TBL] [Abstract][Full Text] [Related]
6. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation.
Kuo YH; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
Hepatol Int; 2021 Apr; 15(2):301-309. PubMed ID: 33665773
[TBL] [Abstract][Full Text] [Related]
7. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy.
Chiu SM; Kuo YH; Wang JH; Hung CH; Hu TH; Lu SN; Chen CH
Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2989-2997.e3. PubMed ID: 32353534
[TBL] [Abstract][Full Text] [Related]
8. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study.
Batirel A; Guclu E; Arslan F; Kocak F; Karabay O; Ozer S; Turanli M; Mert A
Int J Infect Dis; 2014 Nov; 28():153-9. PubMed ID: 25286184
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
10. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
11. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
[TBL] [Abstract][Full Text] [Related]
12. Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment.
Ma TL; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
PLoS One; 2019; 14(10):e0222221. PubMed ID: 31584951
[TBL] [Abstract][Full Text] [Related]
13. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridis GV; Rigopoulou EI; Papatheodoridi M; Zachou K; Xourafas V; Gatselis N; Hadziyannis E; Vlachogiannakos J; Manolakopoulos S; Dalekos GN
Antivir Ther; 2018; 23(8):677-685. PubMed ID: 30044765
[TBL] [Abstract][Full Text] [Related]
14. Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA.
Shi H; Huang M; Lin G; Li X; Wu Y; Jie Y; Chong Y
Biomed Res Int; 2016; 2016():6725073. PubMed ID: 27034945
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
Wang YH; Liao J; Zhang DM; Wu DB; Tao YC; Wang ML; Chen EQ; Tang H
J Med Virol; 2020 Mar; 92(3):302-308. PubMed ID: 31609007
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tenofovir and entecavir in patients who relapsed after pegylated interferon therapy.
Köse Ş; Tatli Kiş T; Atalay S
J Chemother; 2019 Jul; 31(4):209-213. PubMed ID: 30963812
[TBL] [Abstract][Full Text] [Related]
17. Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy.
Lin MJ; Su TH; Liu CJ; Yang HC; Chen CL; Liou JM; Tseng TC; Liu CH; Hong CM; Chen PJ; Kao JH
J Formos Med Assoc; 2023 Jul; 122(7):564-573. PubMed ID: 36872131
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
[TBL] [Abstract][Full Text] [Related]
19. Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B.
Choi HSJ; Hirode G; Chen CH; Su TH; Seto WK; Van Hees S; Papatheodoridi M; Lens S; Wong GLH; Brakenhoff SM; Chien RN; Feld JJ; Sonneveld MJ; Chan HLY; Forns X; Papatheodoridis GV; Vanwolleghem T; Yuen MF; Hsu YC; Kao JH; Cornberg M; Hansen BE; Jeng WJ; Janssen HLA;
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1513-1522.e4. PubMed ID: 35863683
[TBL] [Abstract][Full Text] [Related]
20. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
Kayaaslan B; Akinci E; Ari A; Tufan ZK; Alpat SN; Gunal O; Tosun S; Guner R; Tabak F
Clin Res Hepatol Gastroenterol; 2018 Feb; 42(1):40-47. PubMed ID: 28757048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
